Synergus RWE

Name

Synergus RWE

Legal name

Synergus RWE

Website

https://synergusrwe.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Healthcare Market Access Consulting

NAICS

Scientific Research and Development Services (5417), Management Consulting Services (54161), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN)

akta.pro secondary industries

Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

Keywords

• Market access consulting
• Real world evidence
• Health economics research
• Medical device reimbursement
• HTA strategy services

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Strategic Consulting Services: Professional consulting services for market access strategy development and execution, RWE study design and analysis, and evidence generation for HTA/reimbursement submissions across Western Europe
2. RWE Analysis Services: Real-World Evidence studies developed using best data sets and methodological approaches for various purposes including market access, HTA submissions, and regulatory decision-making

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Synergus RWE develops and executes market access, Real World Evidence (RWE), and Health Economics and Outcomes Research (HEOR) strategies for healthcare companies in Western Europe. The firm provides consulting services to pharmaceutical, medical device, digital health, and diagnostic companies, leveraging a proprietary database of more than 400 data sets to support evidence development, HTA submissions, and reimbursement applications across Germany, France, the Nordics, and broader Europe.

Product overview

Synergus RWE provides consulting services for healthcare companies seeking market access across Western Europe. Their offerings center on three core pillars: Real World Evidence (RWE) generation and analysis, Market Access strategy and execution, and Health Economics and Outcomes Research (HEOR). The company leverages a proprietary database with more than 400 data sets to support evidence development for decision-making. Services span Market Access (covering pharma, medical devices, diagnostics, and digital health), RWE analysis, and HEOR (including cost-effectiveness modeling and value demonstration). The company is part of the IGES group.

Differentiator

Problem solved

Functional benefit

Products and services

• Market Access Services
• Real World Evidence (RWE) Services Real-world evidence generation and analysis using a proprietary database of more than 400 data sets to support healthcare decision-making, HTA submissions, and regulatory decision-making across multiple European markets.
• Health Economics and Outcomes Research (HEOR) Economic evaluation and outcomes research services including cost-effectiveness modelling, budget impact analysis, economic outcomes in clinical studies, and value demonstration for healthcare interventions.
• Statistical Analysis Services Advanced statistical analysis of real-world data using best data sets and methodological approaches to generate insights for market access, HTA submissions, and regulatory decision-making.
• Diagnostic Market Access Services Market access support for in-vitro diagnostic solutions, navigating pathways where most countries do not have formal reimbursement pathways, including HTA and evidence generation for diagnostics.
• Digital Health Market Access Services Market access support for digital health solutions from strategy to application of reimbursement across Europe, leveraging knowledge of evolving reimbursement frameworks including Germany's DIGA pathway and France's PECAN.
• Reimbursement Application Support Hands-on support for reimbursement applications, including identification of local partners and country-specific process navigation for German NUB, 137(h), French PECT, and other European reimbursement applications.
• Evidence Development Strategy Development and execution of European evidence strategies to support decision-makers using Real-World Evidence, including identification of relevant outcomes to demonstrate healthcare benefits.

Quantifiable outcome

• 30 successful NUB applications in 2022 through partner Dr Martin Braun
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• IGES GroupcoreStrategic or Co-development Partner · 14 July 2023Synergus RWE joined the IGES group in July 2023 to become a leader in European market access for medical devices and digital health. The IGES group provides expanded reach across Europe and synergies with sister companies including AiM (Germany market access) and Meditech Access (French market access).
• Dr Martin BrauncoreStrategic or Co-development PartnerDr Martin Braun is a physician and expert in health care system reimbursement strategy. He developed the German DRG system as Head of Medical Department at InEK GmbH (2003-2010) and provides specialized support for NUB applications and 137(h) benefit assessment processes in Germany. Achieved 30 successful NUB applications in 2022.
• AiM (IGES Group)coreStrategic or Co-development PartnerAiM is a sister company within the IGES group focused on market access in Germany. Collaborates with Synergus RWE to provide comprehensive German market access support including eligibility assessments for 137(h) process.
• Meditech Access (IGES Group)coreStrategic or Co-development PartnerMeditech Access is a sister company within the IGES group managing French market access. Synergus RWE references that Meditech Access has managed 4 of 6 successful PECT (temporary reimbursement) applications in France.
• Dr Kristian Kidholm (CIMT Odense University Hospital)minorStrategic or Co-development PartnerSpeaker collaborator for webinars on HTA evaluation of e-health solutions using the MAST (Model for Assessment of Telemedicine) framework. Dr Kidholm is head of research at CIMT and associate professor in health economics at University of Southern Denmark.
• Jan Brönneke (Health Innovation Hub, Germany)minorStrategic or Co-development PartnerSpeaker for webinars on German Digital Reimbursement Act (DVG). Jan Brönneke is Director Law & Economics Health Technologies at Health Innovation Hub, Germany, and provided expertise on the formal pathway for digital reimbursement (DIGA) in Germany.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• Xx.com/Synergus_RWE

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synergus RWE